Express News | Shanghai Pharmaceutical: Terminating clinical trials and subsequent development of three R&D projects including the I010 project

BreakingsApr 30 18:43

Shanghai Pharmaceutical (601607.SH): New specifications for injectable parecoxib sodium have been approved

Gelonghui, April 30 | Shanghai Pharmaceutical (601607.SH) announced that its wholly-owned subsidiary Shangyao Dongying (Jiangsu) Pharmaceutical Co., Ltd., received the “Drug Supplement Application Approval Notice” issued by the State Drug Administration, and the new specification of the drug, 40 mg, was approved. Injectable parecoxib sodium is mainly used for short-term treatment of pain after surgery. It was first developed by Pfizer and marketed in Europe in 2002.

Gelonghui FinanceApr 30 18:36

Express News | Shanghai Pharmaceutical: Terminating clinical trials and subsequent development of the I010, B002 and B003 projects

BreakingsApr 30 18:26

Shanghai Pharmaceuticals Holding's Q1 Profit Rises 2% as Revenue Grows 6%

Shanghai Pharmaceuticals Holding's (SHA:601607, HKG:2607) attributable profit rose 1.62% year over year to 1.54 billion yuan in the first quarter from 1.52 billion yuan, according to separate filings

MT NewswiresApr 29 17:08

Featured announcements | The total amount of AIA share repurchase plans increased to US$12 billion; Sinopec's net profit for the first quarter decreased 8.9% year-on-year

China Shenhua's net profit for the first quarter was 15.884 billion yuan, a year-on-year decrease of 14.7%; China Life Insurance's net profit for the first quarter was 20.644 billion yuan, a decrease of 9.3% year-on-year.

cls.cnApr 29 07:49

Express News | Shanghai Pharmaceutical: It is intended to issue various short-term debt financing products and medium- to long-term debt financing products with a balance equal to RMB 15 billion.

BreakingsApr 26 17:29